185 related articles for article (PubMed ID: 25612787)
1. New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases.
Fukuoka H
Pituitary; 2015 Apr; 18(2):274-8. PubMed ID: 25612787
[TBL] [Abstract][Full Text] [Related]
2. Advances in the medical treatment of Cushing's syndrome.
Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
[TBL] [Abstract][Full Text] [Related]
3. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
4. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
5. [Cushing's syndrome. II. New forms of treatment].
van Aken MO; Feelders RA; van der Lely AJ; Romijn JA; Lamberts SW; de Herder WW
Ned Tijdschr Geneeskd; 2006 Oct; 150(43):2365-9. PubMed ID: 17100127
[TBL] [Abstract][Full Text] [Related]
6. Pituitary-directed medical therapy in Cushing's disease.
Petersenn S; Fleseriu M
Pituitary; 2015 Apr; 18(2):238-44. PubMed ID: 25627118
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
Fleseriu M; Petersenn S
Pituitary; 2015 Apr; 18(2):245-52. PubMed ID: 25560275
[TBL] [Abstract][Full Text] [Related]
8. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
9. Recurrent gain-of-function USP8 mutations in Cushing's disease.
Ma ZY; Song ZJ; Chen JH; Wang YF; Li SQ; Zhou LF; Mao Y; Li YM; Hu RG; Zhang ZY; Ye HY; Shen M; Shou XF; Li ZQ; Peng H; Wang QZ; Zhou DZ; Qin XL; Ji J; Zheng J; Chen H; Wang Y; Geng DY; Tang WJ; Fu CW; Shi ZF; Zhang YC; Ye Z; He WQ; Zhang QL; Tang QS; Xie R; Shen JW; Wen ZJ; Zhou J; Wang T; Huang S; Qiu HJ; Qiao ND; Zhang Y; Pan L; Bao WM; Liu YC; Huang CX; Shi YY; Zhao Y
Cell Res; 2015 Mar; 25(3):306-17. PubMed ID: 25675982
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
11. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome.
Reincke M; Ritzel K; Oßwald A; Berr C; Stalla G; Hallfeldt K; Reisch N; Schopohl J; Beuschlein F
Eur J Endocrinol; 2015 Oct; 173(4):M23-32. PubMed ID: 25994948
[TBL] [Abstract][Full Text] [Related]
12. Relapsing, remitting hypercortisolism in Cushing's disease due to intratumoral hemorrhages in pituitary microadenoma.
Marko NF; Hamrahian AH; Hatipoglu B; Weil RJ
J Clin Neurosci; 2013 May; 20(5):753-6. PubMed ID: 23352667
[TBL] [Abstract][Full Text] [Related]
13. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.
Asari Y; Kageyama K; Sugiyama A; Kogawa H; Niioka K; Daimon M
Endocr J; 2019 Jun; 66(6):515-522. PubMed ID: 30880293
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
16. Medical combination therapies in Cushing's disease.
Vilar L; Naves LA; Machado MC; Bronstein MD
Pituitary; 2015 Apr; 18(2):253-62. PubMed ID: 25647330
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Directed Therapeutic Targets in Cushing Disease.
Theodoropoulou M; Reincke M
J Clin Endocrinol Metab; 2019 Mar; 104(3):925-933. PubMed ID: 30535260
[TBL] [Abstract][Full Text] [Related]
20. [Cushing syndrome: Physiopathology, etiology and principles of therapy].
Chabre O
Presse Med; 2014 Apr; 43(4 Pt 1):376-92. PubMed ID: 24656295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]